Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 02.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
Stammdaten
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Unternehmen & Branche
| Name | Oncotelic Therapeutics, Inc. |
|---|---|
| Ticker | OTLC |
| CIK | 0000908259 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 15,8 Mio. USD |
| Beta | -0,59 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 249,279,832 | 0.59 | 393,088,242 | 262,760,595 | |
| 2025-09-30 | 10-Q | -1,047,365 | 28,156,163 | 9,050,578 | ||
| 2025-06-30 | 10-Q | 277,856 | 0.00 | 26,680,807 | 8,300,969 | |
| 2025-03-31 | 10-Q | -298,716 | 0.00 | 26,668,208 | 8,023,113 | |
| 2024-12-31 | 10-K | -4,523,932 | -0.01 | 26,677,426 | 8,251,631 | |
| 2024-09-30 | 10-Q | -3,304,486 | -0.01 | 26,782,245 | 8,852,564 | |
| 2024-06-30 | 10-Q | -209,837 | 0.00 | 29,935,173 | 12,157,050 | |
| 2024-03-31 | 10-Q | -408,676 | 0.00 | 29,974,410 | 11,834,481 | |
| 2023-12-31 | 10-K | 70,000 | -7,903,093 | -0.02 | 30,014,952 | 12,130,129 |
| 2023-09-30 | 10-Q | 70,000 | 115,309 | 0.00 | 30,096,053 | 12,549,049 |
| 2023-06-30 | 10-Q | -6,757,000 | 30,012,093 | 12,315,203 | ||
| 2023-03-31 | 10-Q | -525,419 | 0.00 | 36,046,360 | 18,746,039 | |
| 2022-12-31 | 10-K | 5,094,981 | 0.01 | 36,116,819 | 19,409,032 | |
| 2022-09-30 | 10-Q | -777,935 | 0.00 | 40,236,762 | 24,187,011 | |
| 2022-06-30 | 10-Q | 16,012,119 | 0.04 | 40,387,968 | 24,359,316 | |
| 2022-03-31 | 10-Q | -4,849,781 | 23,131,551 | 6,360,373 | ||
| 2021-12-31 | 10-K | -9,391,042 | -0.03 | 23,613,351 | 7,955,673 | |
| 2021-09-30 | 10-Q | -1,562,528 | 0.00 | 23,190,270 | 8,009,844 | |
| 2021-06-30 | 10-Q | -3,231,280 | -0.01 | 23,711,250 | 8,912,721 | |
| 2021-03-31 | 10-Q | -2,803,080 | 23,987,362 | 9,951,394 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-07-10 | Trieu Vuong | Director, Officer, 10% Owner, CHAIRMAN AND CEO | Open Market Purchase | 104,000 | 0.01 | 520.00 | +157,0% | |
| 2025-07-09 | Trieu Vuong | Director, Officer, 10% Owner, CHAIRMAN AND CEO | Open Market Purchase | 1 | 0.01 | 0.01 | 0,0% | |
| 2025-07-08 | Trieu Vuong | Director, Officer, 10% Owner, CHAIRMAN AND CEO | Open Market Purchase | 94,736 | 0.01 | 473.68 | +143,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.